N = 22
(No-ocular n = 20, ocular n = 2)
Estadio, n (%)
IIIc
4 (18%)
M1A
5 (23%)
M1B
1 (5%)
M1C
8 (36%)
Nº tratamientos previos (rango)
Mediana
1 (0-8)
0
10 (45%)
1 - 2
4 (18%)
≥ 3
8 (36%)
PD-L1 IHC score, n (%)
Tumor + infiltrado inflamatorio (< 5%)
13 (59%)
Tumor o infiltrado inflamatorio (≥ 5%)
2 (9%)
Atezolizumab + Cobimetinib fase IB
Infante, SMR 2016
